Viewing nowCombinationRabitra Tablet
Ranitidine Hydrochloride 84mg · Tripotassium Bismuth Dicitrate 100mg +1 more
Tablet · Prescription medication · Combination
Telcon R&D Co., Ltd.

MFDS item code 201404551 · Approved 2014.10.01
This product's status changed to Expired on 2024.10.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of acid-related disorders (ulcers, gastritis, reflux esophagitis, etc.); prevention of Mendelson's syndrome
This medication is used to treat stomach and duodenal ulcers, gastritis, Zollinger-Ellison syndrome, and other gastrointestinal disorders. It also alleviates symptoms of gastroesophageal reflux disease and helps prevent ulcers that may occur after surgery. It plays a role in preventing or treating gastric and duodenal ulcers caused by the use of NSAIDs. It is also utilized as a pre-anesthetic medication to prevent Mendelson's syndrome. This medication is effective for the treatment and prevention of various gastrointestinal disorders.
Usually, administer 2 tablets orally twice daily, in the morning and before bedtime, regardless of meals. Gastric and duodenal ulcers: Administer 2 tablets twice daily or 4 tablets once daily at bedtime. In particular, a higher cure rate may be achieved in patients with duodenal ulcers by administering 4 tablets twice daily, in the morning and before bedtime. The dose is the same when used concomitantly to treat ulcers caused by NSAIDs or to prevent gastric and duodenal ulcers during long-term NSAID treatment. NSAID-induced conditions usually heal within 4 weeks, and ulcers usually heal within 8 weeks, although the healing period may occasionally be longer in some patients. For patients with recurrent ulcers who responded well to short-term treatment with this medicine, administer 2 tablets once daily at bedtime as maintenance therapy. Reflux esophagitis: Administer 2 tablets twice daily for 8 weeks or 4 tablets once daily at bedtime. However, the dose may be increased to 4 tablets 4 times daily in patients with severe reflux esophagitis. Zollinger-Ellison syndrome: Begin treatment with an initial dose of 2 tablets 3 times daily, and increase the dose if needed. In severe cases, up to 6 g of ranitidine daily may be administered as directed by a physician. Upper gastrointestinal bleeding due to peptic ulcer, acute stress ulcer, or acute gastric mucosal lesions: Once oral administration is possible, switch from injection to oral administration and administer 2 tablets twice daily. Premedication (prevention of Mendelson syndrome): Administer 2 tablets 2 hours before induction of anesthesia. It is also preferable to administer 2 tablets the night before surgery.
This medication should not be used by patients undergoing dialysis or patients with kidney function issues. Patients who have experienced allergic reactions to this medication or its components, those with a history of acute porphyria, patients who have undergone upper gastrointestinal surgery, pregnant women or those who may become pregnant, premature infants and newborns, and patients on potassium-restricted diets should also refrain from taking this medication. Patients with impaired liver function or a history of drug allergies, the elderly, patients with a history of kidney disease, and patients taking non-steroidal anti-inflammatory drugs should use this medication with caution, particularly since it can mask gastric cancer symptoms. Therefore, patients with gastric ulcers or middle-aged patients who present new dyspeptic symptoms should have malignancy ruled out prior to treatment. Patients with Helicobacter pylori infection in gastric or duodenal ulcers should receive concomitant treatment to eradicate the bacteria, and special caution is needed for patients in critical care, those with hypophosphatemia, and patients with swallowing difficulties due to the possible risk of complications from this medication. Rarely, anaphylaxis or hypersensitivity reactions such as skin rashes, hives, or angioedema may occur, so if symptoms develop, administration should be stopped immediately and medical advice should be sought. Blood-related abnormalities such as reversible leukopenia and thrombocytopenia have been reported rarely, and symptoms such as liver dysfunction, arrhythmia, gastrointestinal symptoms, neuropsychiatric disturbances, musculoskeletal pain, and skin rashes may also occur; immediate reporting of unusual symptoms is necessary. Long-term use is not recommended and regular monitoring of blood, liver, and kidney function is required during treatment. Dizziness or drowsiness may occur during the use of this medication, so it is advisable to avoid driving or operating hazardous machinery. Moreover, this medication can interact with other drugs, so it is essential to inform medical personnel if taking other medications, particularly since caution is needed in conjunction with certain antibiotics or anticoagulants. It is safest for pregnant or breastfeeding women to avoid this medication, as safety and efficacy in pediatrics have not been established, and use is not recommended. In case of overdose, emergency measures such as vomiting or gastric lavage may be needed. Since this medication reduces gastric acid secretion, it may promote bacterial growth in the stomach, so regular eye examinations may be necessary with long-term use.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture entry and should be kept at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's efficacy and prevents degradation.
Round white film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationRanitidine Hydrochloride 84mg · Tripotassium Bismuth Dicitrate 100mg +1 more
Tablet · Prescription medication · Combination
Telcon R&D Co., Ltd.
CombinationRanitidine Hydrochloride 84mg · Tripotassium Bismuth Dicitrate 100mg +1 more
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 84mg · Tripotassium Bismuth Dicitrate 100mg +1 more
Tablet · Prescription medication · Combination
Nexpharm Korea Co., Ltd.
CombinationRanitidine Hydrochloride 84mg · Tripotassium Bismuth Dicitrate 100mg +1 more
Tablet · Prescription medication · Combination
HUONS BioScience Co., Ltd.
CombinationRanitidine Hydrochloride 84mg · Tripotassium Bismuth Dicitrate 100mg +1 more
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
CombinationRanitidine Hydrochloride 84mg · Tripotassium Bismuth Dicitrate 100mg +1 more
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
Ranitidine Hydrochloride 84mg · Sucralfate Hydrate 300mg +1 more
Tablet · Prescription medication · Combination
Korea Pavise Pharmaceutical Co., Ltd.
Ranitidine Hydrochloride 84mg · Sucralfate Hydrate 300mg +1 more
Tablet · Prescription medication · Combination
Kwangdong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.